Following the full nationwide implementation of the renewed national centralized drug procurement, the four selected products of Beijing Honglin Pharmaceutical Co., Ltd. — JUPOPINE^® Nifedipine Controlled-release Tablets, RoToFier^® Glipizide Extended Release Tablets, JUPOSHU^® Amlodipine Besylate Tablets, and JUPOPHON^® Ibuprofen Sustained-release Capsules— have been officially adopted nationwide, with supply operations proceeding in a steady and orderly manner.

As a specialized enterprise in extended- and sustained-release formulations, all four of our selected products have officially passed consistency evaluation, with quality and efficacy equivalent to those of the Reference Listed Drug (RLD). Supported by our strong market presence, these products have earned high recognition: JUPOPINE^® and RoToFier^® ranked first in this round of national centralized drug procurement projected volume among consistency-approved manufacturers for their respective products, while JUPOPHON^® and JUPOSHU^® ranked fourth and fifth respectively among peers. These results fully reflect the trust that clinicians and the market place in our products.

GoeGoe Honglin Pharm. made thorough arrangements and adequate preparations in advance——we have strengthened the foundation for sustained and stable supply by optimizing production capacity scheduling, enhancing raw material inventory, and improving the logistics and distribution system. At present, our products are smoothly listed on procurement platforms with efficient delivery, ensuring adequate, timely and stable clinical supply to effectively meet the medication needs of medical institutions at all levels.